Yongcong Tan

机构：Jiangsu T-mab BioPharma (China)

发表论文 8 篇 · 总被引 474 次 · h-index 4

代表论文

• Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study (2021 · Science · 被引 341)
• Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection (2020 · Cell Research · 被引 98)
• hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants (2021 · Cell Discovery · 被引 15)
• An Engineered IgG–VHH Bispecific Antibody against SARS‐CoV‐2 and Its Variants (2022 · Small Methods · 被引 9)
• Abstract LB128: A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma (2024 · Cancer Research · 被引 4)
• Abstract 2712: Development of GB268, a tri-specific antibody targeting PD-1/CTLA-4/VEGF, with enhanced anti-tumor efficacy and reduced toxicity in pre-clinical studies (2024 · Cancer Research · 被引 4)